BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
174 hedge funds and large institutions have $303M invested in bluebird bio in 2022 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 54 increasing their positions, 45 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
48% less capital invested
Capital invested by funds: $581M → $303M (-$279M)
54% less call options, than puts
Call options by funds: $961K | Put options by funds: $2.09M
Holders
174
Holding in Top 10
–
Calls
$961K
Puts
$2.09M
Top Buyers
| 1 | +$26.8M | |
| 2 | +$7.52M | |
| 3 | +$5.27M | |
| 4 |
Renaissance Technologies
New York
|
+$4.56M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$3.3M |
Top Sellers
| 1 | -$52M | |
| 2 | -$23.5M | |
| 3 | -$9.11M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.33M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$5.38M |